Introduction to IgA Nephropathy and Endocapillary Hypercellularity

IgA Nephropathy Overview

An introduction to the complex condition of IgA nephropathy.

Disease Introduction

Introducing IgA nephropathy and its impact on kidney health.

What is IgA Nephropathy

A chronic kidney disease caused by IgA deposits in the kidneys.

Burden of Disease

Discussing the progressive nature and the challenges it poses.

Limited Treatments

Highlighting the current scarcity of effective treatment options.

Challenges in Treatment

Exploring the reasons behind the limited therapeutic options for IgA nephropathy.

Incomplete Understanding

The disease mechanisms are not fully understood, complicating treatment development.

Variable Presentation

Patients show different symptoms, making standard treatment difficult.

Immature Risk Prediction

Risk assessment tools are not fully developed, hindering personalized medicine.

Clinical Trial Challenges

Difficulties in conducting trials due to disease's slow progression and diverse effects.

Disease Mechanisms

Delving deeper into the biological underpinnings of IgA nephropathy.

IgA Dysregulation

Abnormal IgA production is a key factor in disease onset.

Polymeric IgA1

Introduction to the role and forms of polymeric IgA1 in the disease.

Mucosal Surfaces Role

How IgA1 produced at mucosal surfaces leads to serum involvement.

Four Hit Hypothesis

Discussing the theory that explains the progression of IgA nephropathy.

Pathways of Inflammation and Fibrosis

Investigating how IgA1 deposits trigger various inflammatory responses.

Variable Inflammatory Response

Understanding why responses to IgA1 deposits vary between individuals.

Role of the Complement System

Exploring the involvement of different complement pathways in the disease.

Clinical Phenotype Diversity

How the mechanisms translate into varied disease manifestations in patients.

Epidemiology and Clinical Presentation

Evaluating the spread and symptoms of IgA nephropathy.

Epidemiological Data

Discussing the prevalence and demographic distribution of the disease.

Clinical Symptom Variability

Highlighting the range of symptoms that patients can exhibit.

Prognostic Risk Factors

Identifying factors that contribute to worsening of the disease.

Risk Prediction and Management

Understanding current tools for prognostics and their limitations in practice.

IgAN Risk Tool Limitations

The IgAN risk prediction tool's inadequacies and need for refinement.

Available Treatments

Covering the existing generic treatments and their insufficiency.

Systemic Immunosuppressants

The risks associated with the available disease-modifying treatments.

The Future of IgAN Treatment

Looking at the advancements and challenges in treating IgA nephropathy.

New Drugs Development

Highlighting the emergence of new treatments due to changes in trial endpoints.


Example of a recently approved drug that targets the disease mechanisms.

Precision Medicine

Discussing the need for personalized treatments based on individual patient data.

Targeting E1 Hypercellularity

Exploring a potential marker for treatment responsiveness in IgA nephropathy.

Significance of E1

The potential of endocapillary hypercellularity as a biomarker for disease.

Reversibility of E1

Evidence supporting the reversibility of E1 with specific treatments.

Safe Treatments Need

The necessity for targeted and safe remedies for patients with E1.